1257997-17-3

Usage

Molecular structure

The compound is composed of a cyclohexyl group, a boron-containing dioxaborolane group, and a pyrazole ring.

Stereochemistry

The compound has a specific stereochemistry, with the R configuration at both the 1 and 4 positions of the cyclohexyl group.

Protecting group

The tert-butyl dimethyl silyl (TBS) group is present in the compound, providing protection for reactive functional groups during synthesis processes.

Boron-containing group

The compound contains a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, which can participate in various bond-forming reactions.

Reactivity

The compound is designed to have specific reactivity for use in various chemical reactions and applications.

Applications

The compound has potential uses in the development of advanced materials and pharmaceuticals due to its unique structure and reactivity.

Organic synthesis

The compound is used in organic synthesis and material science.

Molecular weight

Approximately 391.64 g/mol (calculated from the molecular formula).

Solubility

The compound's solubility is not provided in the material, but it may be soluble in organic solvents such as dichloromethane, tetrahydrofuran, or dimethyl sulfoxide, depending on the specific functional groups and their interactions.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1257997-18-4 1-(trans-4-{[tert-Butyl(dimethyl)silyl]oxy}cyclohexyl)-4-iodo-1H-pyrazole 
• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 23511-05-9 toluene-4-sulfonic acid 1,4-dioxa-spiro[4.5]dec-8-yl ester 
• 1175275-29-2 4-iodo-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazole 
• 1227611-94-0 4-(4-iodo-1H-pyrazol-1-yl)cyclohexanone 
• 1227611-92-8 4-(4-iodo-1H-pyrazol-1-yl)cyclohexanol 

Downstream Products

• 1448429-57-9 2-(quinolin-6-ylmethyl)-6-{1-[(1R,4R)-4-(tert-butyldimethylsilyloxy)cyclohexyl]-1H-pyrazol-4-yl}-1H-indazole 
• 1448429-53-5 1-(quinolin-6-ylmethyl)-6-[1-((1R,4R)-4-hydroxy-cyclohexyl)-1H-pyrazol-4-yl]-1H-indazole 
• 1448429-52-4 1-(quinolin-6-ylmethyl)-6-{1-[(1R,4R)-4-(tert-butyldimethylsilyloxy)cyclohexyl]-1H-pyrazol-4-yl}-1H-indazole 
• 1448429-58-0 2-(quinolin-6-ylmethyl)-6-[1-((1R,4R)-4-hydroxy-cyclohexyl)-1H-pyrazol-4-yl]-1H-indazole 
• 1448429-61-5 6-{1-[(1R,4R)-4-(tert-butyldimethylsilyloxy)cyclohexyl]-1H-pyrazol-4-yl}-1H-indazole 
• 1326714-46-8 C₂₂H₃₀Cl₂N₄O₂Si 
• 1413875-99-6 5-[1-(trans-4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)-1H-pyrazol-4-yl]-3-{1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]-2-fluoro-2,2-bis(phenylsulfonyl)ethyl}-1H-pyrrolo[2,3-b]pyridine 
• 1413875-84-9 5-[1-(trans-4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)-1H-pyrazol-4-yl]-3-[1-(2-chloro-3-fluoro-6-methoxyphenyl)-2-fluoro-2,2-bis(phenylsulfonyl)ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1413868-61-7 trans-4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]-2-fluoroethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-1-yl]cyclohexanol 
• 1413868-56-0 trans-4-[4-(3-{(1R)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]-2-fluoroethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-1-yl]cyclohexanol 
• 1413875-95-2 trans-4-[4-(3-{-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]-2-fluoroethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-1-yl]cyclohexanol 
• 1413876-18-2 trans-4-[4-(3-{-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]-2-fluoroethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-1-yl]cyclohexanol 
• 1413868-51-5 trans-4-(4-{3-[(1S)-1-(2-chloro-3-fluoro-6-methoxyphenyl)-2-fluoroethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-pyrazol-1-yl)cyclohexanol 
• 1413868-46-8 trans-4-(4-{3-[(1R)-1-(2-chloro-3-fluoro-6-methoxyphenyl)-2-fluoroethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-pyrazol-1-yl)cyclohexanol 

Relevant academic research and scientific papers

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.